Epigenomics Past Earnings Performance
Past criteria checks 0/6
Epigenomics has been growing earnings at an average annual rate of 13.5%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 21.8% per year.
Key information
13.5%
Earnings growth rate
32.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 21.8% |
| Return on equity | -52.1% |
| Net Margin | -1,279.5% |
| Next Earnings Update | 21 Apr 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Epigenomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 1 | -7 | 7 | 6 |
| 30 Jun 22 | 6 | -3 | 8 | 5 |
| 31 Mar 22 | 6 | -4 | 8 | 4 |
| 31 Dec 21 | 6 | -2 | 8 | 3 |
| 30 Sep 21 | 6 | -3 | 8 | 2 |
| 30 Jun 21 | 1 | -9 | 6 | 2 |
| 31 Mar 21 | 1 | -10 | 7 | 3 |
| 31 Dec 20 | 1 | -12 | 7 | 4 |
| 30 Sep 20 | 1 | -16 | 8 | 5 |
| 30 Jun 20 | 1 | -16 | 8 | 6 |
| 31 Mar 20 | 1 | -17 | 9 | 7 |
| 31 Dec 19 | 1 | -17 | 9 | 7 |
| 30 Sep 19 | 1 | -14 | 10 | 8 |
| 30 Jun 19 | 1 | -14 | 10 | 7 |
| 31 Mar 19 | 2 | -12 | 9 | 6 |
| 31 Dec 18 | 2 | -13 | 9 | 6 |
| 30 Sep 18 | 2 | -11 | 8 | 6 |
| 30 Jun 18 | 2 | -10 | 7 | 5 |
| 31 Mar 18 | 2 | -11 | 8 | 5 |
| 31 Dec 17 | 2 | -10 | 8 | 4 |
| 30 Sep 17 | 3 | -9 | 8 | 4 |
| 30 Jun 17 | 3 | -10 | 10 | 4 |
| 31 Mar 17 | 4 | -9 | 9 | 4 |
| 31 Dec 16 | 4 | -11 | 10 | 5 |
| 30 Sep 16 | 3 | -11 | 9 | 5 |
| 30 Jun 16 | 3 | -11 | 9 | 5 |
| 31 Mar 16 | 2 | -10 | 7 | 6 |
Quality Earnings: EPGN.Y is currently unprofitable.
Growing Profit Margin: EPGN.Y is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EPGN.Y is unprofitable, but has reduced losses over the past 5 years at a rate of 13.5% per year.
Accelerating Growth: Unable to compare EPGN.Y's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EPGN.Y is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: EPGN.Y has a negative Return on Equity (-52.07%), as it is currently unprofitable.